Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,536 questions · 2,637 findings · 315 reviews

No studies found 608 · 23.1%GRADE not reported 488 · 18.5%Very low 688 · 26.1%Low 540 · 20.5%Moderate 249 · 9.4%High 64 · 2.4%

Intervention not reported

Interferon beta‐1b (Betaferon) No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

It is very uncertain whether the intervention changes interferon beta‐1b (Betaferon) No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

The intervention showed no clear difference in fingolimod (Direct evidence; 2 RCTs; 2355 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Glatiramer acetate (Direct evidence; 3 RCTs; 2371 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

The intervention showed no clear difference in glatiramer acetate (Direct evidence; 3 RCTs; 2371 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Interferon beta‐1b (Betaferon) No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

The intervention showed no clear difference in interferon beta‐1b (Betaferon) No direct evidence (moderate certainty).

1 finding from 1 review

Intervention not reported

Laquinimod (Direct evidence; 3 RCTs; 3457 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes laquinimod (Direct evidence; 3 RCTs; 3457 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (very low certainty).

1 finding from 1 review

Intervention not reported

Natalizumab (Direct evidence; 1 RCT; 939 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

The intervention showed no clear difference in natalizumab (Direct evidence; 1 RCT; 939 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ocrelizumab No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ofatumumab No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ozanimod No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (very low certainty).

1 finding from 1 review